nonaBDEs in the GC injector by spiking three BDE-209 concentrations (100, 500, 1000 ng) into solvent and computing the average for each BDE congener. Concentrations of 4 and 20 ng/mL were also used but no degradation to was detected. Conversion rates (mean + standard deviation) were: 2.8 + 1.2% for BDE-206, 1.7 + 0.3% for BDE-207, and 0.95 + 0.1% for BDE-208. We corrected for the conversion of BDE-209 in each sample as follows: on a molar basis, 3% to  we did not observe any conversion of BDE-209 to The quality control results for solvent method blanks, low and high level analyte spikes to dust, and duplicate samples are shown in Supplemental Material, Table S1. The method detection limit (MDL) was based on the concentration giving approximately 3 times the matrix/instrument noise level (which were similar because of the high degree of sample cleanup). We estimated that there was about 0.5% unlabeled BDE-209 in the labeled SRS (13C12 BDE 209). Because of this low contribution to BDE 209 and the high native levels of BDE 209, we did not correct for this in the actual samples. The recoveries of the 4 SRSs served as important metrics to evaluate method performance on a sample-by-sample basis and to correct the concentrations of the matched PBDEs (i.e., those possessing similar numbers of bromines; see Table 1 , footnote c).
Recoveries of SRS BDE-126 in samples (n=448), spikes (n=28), and duplicates (n=56) were: 78 ± 12%, 78 ± 11%, and 80 ± 12%, respectively. Recoveries of SRS BDE-177 in samples, spikes, and duplicates were: 69 ± 10%, 73 ± 12%, and 70 ± 11%, respectively. Recoveries of SRS BDE-195 in samples, spikes, and duplicates were: 68 ± 12%, 71 ± 11%, and 69 ± 11%, respectively.
Recoveries of SRS 13 C 12 BDE-209 in samples, spikes, and duplicates were: 66 ± 14%, 70 ± 15%, and 66 ± 14%, respectively. Deca-BDEs: BDE-206, BDE-207, BDE-208 a Values below the MDL were imputed based on a lognormal distribution and accounting for residence location (urban, suburban, rural) and
year of sampling.
